<p>Inhibrx (NASDAQ: INBX) 在 2025 年 10 月报告了 Ozekibart (INBRX-109) 注册试验的积极顶线结果后，经历了一波急剧反弹。该股在短时间内上涨超过 150%，引起了投资者的广泛关注。然而，当从 Adhishthana 框架的角度分析这一走势时，特别是在分析该股在月度周期中的定位时，开始显现出结构性风险。</p>
<h3><strong>分析 Inhibrx 的月度结构</strong></h3>
<p>Inhibrx 目前处于其 18 阶段 Adhishthana 周期的第 2 阶段。在这一原则下，第 2 阶段分为两个不同的部分。第一部分是 Sankhya 期，通常以整合或修正行为为特征。接下来是 Buddhi 期，此时股票通常会经历强劲、持续的上涨动能。</p>
<p>在 Inhibrx 的案例中，该股仍在第 2 阶段的早期 Sankhya 部分中徘徊。与其整合或修正相反，该股却出现了急剧的上涨，造成了与预期结构的偏离。历史上，在 Sankhya 期间的这种过早强势往往会导致周期后期的不稳定。</p>
<p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2025/12/24113214/INBX-Stock-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2025/12/24113214/INBX-Stock-.png"/></p>
<p>图 1 Inhibrx 第 2 阶段（来源：Adhishthana.com）</p>
<p>当股票在第 2 阶段的早期部分急剧上涨时，通常会在过渡到 Buddhi 阶段后面临急剧修正。我们在 Lamb Weston 观察到了类似的情况，在 Sankhya 期间的过早反弹后，一旦 Buddhi 开始，该股下跌超过 60%。</p>
<p>参考：是什么驱动 Lamb Weston 的持续低迷表现</p>
<p>目前，Inhibrx 仍处于初始 Sankhya 窗口内，正式过渡到 Buddhi 仍需数月时间。这为近期的反弹进一步延续留出了空间。然而，从结构上看，这一走势并未发生在最佳阶段，这引发了对其可持续性的质疑。</p>
<h3><strong>投资者展望</strong></h3>
<p>由于反弹发生在周期的不利点，Inhibrx 的中期展望值得谨慎。希望在当前水平追逐该股的投资者可能需要重新评估，因为这种强势与 Adhishthana 周期的自然节奏并不一致。</p>
<p>在 Ozekibart 公告之前建立头寸的投资者可以继续持有，但应意识到当前的反弹在 Adhishthana 框架下存在结构性风险。尽管该股在短期内可能继续保持看涨动能，但这一走势的时机表明，并非所有风险都已显现。</p>
<p>总之，Inhibrx 在表面上可能仍然看起来强劲，但在反弹背后存在着投资者不应忽视的错位。</p>
<p><strong><em>Benzinga 免责声明：本文来自未付费的外部贡献者。它不代表 Benzinga 的报道，并且未经过内容或准确性的编辑。</em></strong></p>

INBX

<p>Inhibrx 的股票在 Ozekibart 的积极试验结果公布后上涨超过 150%，但使用 Adhishthana 框架的分析揭示了结构性风险。该股票处于第二阶段的 Sankhya 期，通常以整合为特征，但它却急剧上涨。这种过早的强劲表现可能导致在过渡到 Buddhi 阶段时的不稳定。投资者应保持谨慎，因为此次上涨的时机与周期不符，存在中期风险</p>

<p>Inhibrx (NASDAQ: INBX) has staged a sharp rally after reporting positive topline results from its registrational trial of Ozekibart (INBRX-109) back in October 2025. The stock surged more than 150% in a short span, drawing significant investor attention. However, when the move is examined through the lens of the Adhishthana framework, a structural risk begins to surface, particularly when analysing the stock's positioning on the monthly cycle.</p>
<div class="lb-trans"><p>Inhibrx (NASDAQ: INBX) 在 2025 年 10 月报告了 Ozekibart (INBRX-109) 注册试验的积极顶线结果后，经历了一波急剧反弹。该股在短时间内上涨超过 150%，引起了投资者的广泛关注。然而，当从 Adhishthana 框架的角度分析这一走势时，特别是在分析该股在月度周期中的定位时，开始显现出结构性风险。</p>
</div><h3><strong>Analysing Inhibrx's Monthly Structure</strong></h3>
<div class="lb-trans"><h3><strong>分析 Inhibrx 的月度结构</strong></h3>
</div><p>Inhibrx is currently in Phase 2 of its 18-phase Adhishthana cycle on the monthly charts. Under the principles, Phase 2 unfolds in two distinct segments. The first is the Sankhya period, which is typically characterised by consolidation or corrective behaviour. This is followed by the Buddhi period, where stocks often experience strong, sustained upside momentum.</p>
<div class="lb-trans"><p>Inhibrx 目前处于其 18 阶段 Adhishthana 周期的第 2 阶段。在这一原则下，第 2 阶段分为两个不同的部分。第一部分是 Sankhya 期，通常以整合或修正行为为特征。接下来是 Buddhi 期，此时股票通常会经历强劲、持续的上涨动能。</p>
</div><p>In Inhibrx's case, the stock is still navigating the early Sankhya portion of Phase 2. Instead of consolidating or correcting, the stock has delivered a sharp upside move, creating a deviation from the expected structure. Historically, such premature strength during Sankhya often leads to instability later in the cycle.</p>
<div class="lb-trans"><p>在 Inhibrx 的案例中，该股仍在第 2 阶段的早期 Sankhya 部分中徘徊。与其整合或修正相反，该股却出现了急剧的上涨，造成了与预期结构的偏离。历史上，在 Sankhya 期间的这种过早强势往往会导致周期后期的不稳定。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://contributor-assets.benzinga.com/wp-content/uploads/2025/12/24113214/INBX-Stock-.png" alt="" original-src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/12/24113214/INBX-Stock-.png"/></p>
<p>Fig.1 Inhibrx Phase 2 (Source: Adhishthana.com)</p>
<div class="lb-trans"><p>图 1 Inhibrx 第 2 阶段（来源：Adhishthana.com）</p>
</div><p>When stocks rally aggressively in the early part of Phase 2, they tend to face sharp corrections once they transition into the Buddhi phase. We observed a similar setup in Lamb Weston, where a premature rally during Sankhya was followed by a collapse of more than 60% once Buddhi began.</p>
<div class="lb-trans"><p>当股票在第 2 阶段的早期部分急剧上涨时，通常会在过渡到 Buddhi 阶段后面临急剧修正。我们在 Lamb Weston 观察到了类似的情况，在 Sankhya 期间的过早反弹后，一旦 Buddhi 开始，该股下跌超过 60%。</p>
</div><p>Refer: What's Driving Lamb Weston's Sustained Underperformance</p>
<div class="lb-trans"><p>参考：是什么驱动 Lamb Weston 的持续低迷表现</p>
</div><p>At present, Inhibrx remains within the initial Sankhya window, and the formal transition into Buddhi is still months away. This leaves room for the rally to extend further in the near term. However, structurally, the move is not occurring at the optimal phase, which raises questions about its sustainability.</p>
<div class="lb-trans"><p>目前，Inhibrx 仍处于初始 Sankhya 窗口内，正式过渡到 Buddhi 仍需数月时间。这为近期的反弹进一步延续留出了空间。然而，从结构上看，这一走势并未发生在最佳阶段，这引发了对其可持续性的质疑。</p>
</div><h3><strong>Investor Outlook</strong></h3>
<div class="lb-trans"><h3><strong>投资者展望</strong></h3>
</div><p>With the rally unfolding at an unfavourable point in the cycle, Inhibrx's medium-term outlook warrants caution. Investors looking to chase the stock at current levels may want to reassess, as the strength is not aligned with the natural rhythm of the Adhishthana cycle.</p>
<div class="lb-trans"><p>由于反弹发生在周期的不利点，Inhibrx 的中期展望值得谨慎。希望在当前水平追逐该股的投资者可能需要重新评估，因为这种强势与 Adhishthana 周期的自然节奏并不一致。</p>
</div><p>Those who established positions prior to the Ozekibart announcement can continue to hold, but should remain aware that the current rally carries structural risks under the Adhishthana framework. While the stock may continue to trade with bullish momentum in the short term, the timing of the move suggests that not all risks are visible yet.</p>
<div class="lb-trans"><p>在 Ozekibart 公告之前建立头寸的投资者可以继续持有，但应意识到当前的反弹在 Adhishthana 框架下存在结构性风险。尽管该股在短期内可能继续保持看涨动能，但这一走势的时机表明，并非所有风险都已显现。</p>
</div><p>In summary, Inhibrx may still look strong on the surface, but beneath the rally lies a misalignment that investors should not ignore.</p>
<div class="lb-trans"><p>总之，Inhibrx 在表面上可能仍然看起来强劲，但在反弹背后存在着投资者不应忽视的错位。</p>
</div><p><strong><em>Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.</em></strong></p>
<div class="lb-trans"><p><strong><em>Benzinga 免责声明：本文来自未付费的外部贡献者。它不代表 Benzinga 的报道，并且未经过内容或准确性的编辑。</em></strong></p>
</div>

为什么 Inhibrx 最近的强势可能难以持续